Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03571997 Recruiting - Clinical trials for Lymphoblastic Lymphoma

Study of Prognostic Factors in Adult Lymphoblastic Lymphoma

Start date: June 15, 2018
Phase:
Study type: Observational

Retrospective observational study with systematic collection of data on filiation (age at diagnosis and sex), clinical data (IPI, ECOG, early response to chemotherapy, overall response to chemotherapy), biological (strain B or T, infiltration of the nervous system central [CNS], bone marrow [MO], lactate dehydrogenase (LDH) level at the time of diagnosis, as well as genetic patients included in the study, as well as the PETHEMA protocol used in the treatment of same patients The study will review the PETHEMA protocols from 2003 to the present

NCT ID: NCT03571828 Terminated - Clinical trials for Follicular Lymphoma (FL)

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Start date: October 29, 2018
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of AMG 562 in adult subjects with DLBCL, MCL, or FL. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (e.g., recommended phase 2 dose [RP2D])

NCT ID: NCT03571568 Recruiting - Clinical trials for Indolent B-Cell Non-Hodgkin Lymphoma

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Start date: May 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

NCT ID: NCT03571308 Completed - Clinical trials for Non Hodgkin Lymphoma

A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)

ACCEPT
Start date: June 2, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Previously untreated CD20 positive diffuse large B-cell lymphoma (DLBCL) requiring full course chemoimmunotherapy.

NCT ID: NCT03570892 Active, not recruiting - Clinical trials for Non-Hodgkin Lymphoma

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

BELINDA
Start date: May 7, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.

NCT ID: NCT03569995 Recruiting - Clinical trials for Primary CNS Lymphoma

[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma

Start date: November 30, 2018
Phase: Phase 2
Study type: Interventional

This study was conducted to evaluate the 2-year progression free survival rate of elderly patients with primary CNS lymphoma followed by combination of rituximab and methotrexate followed by rituximab and cytarabine.

NCT ID: NCT03569696 Recruiting - Lymphoma, B-Cell Clinical Trials

Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy

NivoM
Start date: October 8, 2018
Phase: Phase 2
Study type: Interventional

This trial is designed as a unicenter, single arm phase II trial. The aim of the trial is to test whether prognosis of high-risk Aggressive B cell Lymphoma (ABCL) patients who are in complete remission (CR) post immunochemotherapy can be improved by 2year nivolumab maintenance therapy. Participants will be recruited from Chaim Sheba Medical Center as well as from other medical centers in Israel through the Israeli lymphoma group. Therapy will be treated in Chaim Sheba Medical Center.

NCT ID: NCT03568929 Completed - Clinical trials for Follicular Non-Hodgkin's Lymphoma Refractory

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma

ZEUS
Start date: May 25, 2018
Phase:
Study type: Observational

The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).

NCT ID: NCT03568461 Active, not recruiting - Follicular Lymphoma Clinical Trials

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

ELARA
Start date: November 12, 2018
Phase: Phase 2
Study type: Interventional

This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.

NCT ID: NCT03567876 Active, not recruiting - Clinical trials for Lymphoma, Mantle-Cell

Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Start date: September 3, 2018
Phase: Phase 2
Study type: Interventional

Prospective, multicenter, phase II trial designed to evaluate whether the addition of Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with mantle cell lymphoma improves the results of the standard R-BAC, in terms of Progression Free Survival.